Ocumension Therapeutics NMPA accepts dexamethasone intraocular suspension application
Ocumension Therapeutics said its dexamethasone intraocular suspension application was accepted by NMPA.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.